20 Future Swedish HealthTech and MedTech Leaders

Nelson Advisors
Mar 26
15 min read

The Swedish medical technology and digital health ecosystem is currently navigating a pivotal transition from early-stage innovation toward global commercial scale. As of 2025, the sector is defined by a robust convergence of computational biology, artificial intelligence, and decentralised care models, positioning Sweden as a primary engine of the European "TechBio" movement.

The industry comprises over 2,100 medtech companies, which, alongside the broader life science sector, generated approximately $46.8 Billion in net turnover in 2022, a 54 % increase compared to 2014. This growth is supported by a highly specialised workforce that has expanded by 18% since 2019, reflecting the sector's resilience and its role as the second-largest export sector in Sweden, accounting for nearly 10 percent of total product exports.

The national strategic framework is anchored by "Vision for eHealth 2025," an ambitious government initiative aimed at making Sweden the world leader in leveraging digitalization to provide equitable, high-quality healthcare.

This vision is underpinned by substantial regional investments in IT infrastructure, totalling approximately $1.22 Billion annually.Furthermore, the decentralisation of care is accelerating, with the home healthcare market projected to reach $8.1 Billion by 2030, representing a compound annual growth rate (CAGR) of 10.3 percent from 2025 to 2030. While digital services currently represent the largest revenue segment, equipment and remote monitoring technologies are identified as the most profitable and fastest-growing categories.

Market Dynamics and The Investment Landscape

The investment climate for Swedish healthtech and medtech has evolved into a disciplined, result-oriented phase following the broader "biotech winter" of previous years. In the first eleven months of 2025, 100 Swedish startups secured nearly $1.5 Billion in funding.

However, the distribution of this capital is increasingly concentrated in higher-quality assets that demonstrate clear clinical impact and international scalability. Investors are prioritising "mega-deals" and late-stage rounds (Series B and beyond), particularly for companies integrating artificial intelligence into provider operations and back-office automation.

Swedish HealthTech and MedTech Funding Trends 2025

Metric	Value	Industry Significance
Total Startups Funded (Jan-Nov 2025)	100	Reflects a vibrant commitment to innovation despite economic headwinds.
Total Capital Raised ($B)	1.46	Demonstrates sustained investor appetite for Swedish deep tech.
Largest Deal (Lovable, Series A)	$200 M	Signals a return of mega-deals for high-traction software platforms.
Total MedTech/Life Science Turnover	$46.8 Bn	Underscores the sector's contribution to national GDP (7.8% in 2024).
Export Value of Tech Services	~SEK 400 Bn	Highlights the importance of intangible exports and digital health services.

Note: Data represents status as of November 2025 based on tracked funding rounds and industry reports.

The Swedish pharmaceutical and medtech pipeline remains a cornerstone of the ecosystem, with 518 projects currently being conducted by 152 Swedish-headquartered companies. A defining characteristic of this landscape is company diversity; unlike other mature European markets that may rely on a few "Big Pharma" entities, Sweden’s pipeline is driven by micro-enterprises, with 73 % of companies employing fewer than ten people. This structure fosters a diverse range of development stages and modalities, which analysts view as a critical strategic advantage.

Regulatory Catalysts and Strategic Bottlenecks

The transition toward 2026 is marked by significant regulatory milestones and the resolution of long-standing infrastructure challenges. Compliance with the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) is now mandatory for any firm seeking to maintain or establish a foothold in the European market.Swedish firms are also preparing for the European Health Data Space (EHDS), which is expected to require between €150 Million and €400 Million in regional investment by 2028 to enable data unification for secondary use.

A critical technological hurdle remains the "FHIR Gap", the inconsistent adoption of the Fast Healthcare Interoperability Resources standard across regional health systems. This lack of interoperability, combined with the legacy burden of fragmented Electronic Health Record (EHR) systems, continues to limit the speed at which innovative solutions can scale from pilot projects to national implementation. The delay of the National Medication List (NLL), now pushed to 2028 or 2030 in some regions, serves as a prominent example of these infrastructure constraints.

Analysis of Top 20 Swedish Companies for Growth and M&A

The following 20 companies represent the elite tier of the Swedish healthtech and medtech landscape, selected for their technological differentiation, fundraising momentum and potential as strategic acquisition targets for global healthcare leaders.

1. Neko Health: The AI-Driven Preventive Diagnostics Leader

Neko Health, co-founded by Daniel Ek and Hjalmar Nilsonne, is perhaps the most visible representative of Sweden’s "TechBio" movement. The company has developed a full-body scanning system that integrates advanced sensors, high-resolution imaging, and artificial intelligence to perform comprehensive preventive health screenings in a single clinical visit. By collecting and interpreting millions of health data points per patient, Neko Health aims to identify risk factors for cardiovascular disease, metabolic disorders, and skin cancer before clinical symptoms emerge.

The strategic significance of Neko Health lies in its ability to shift the healthcare paradigm from reactive treatment to proactive maintenance. Its "mega-deal" funding round in 2025, reportedly the largest of its kind, signals a broader industry confidence in the value of aggregated health data for longitudinal wellness tracking. For strategic acquirers like GE HealthCare or Siemens Healthineers, Neko Health offers a commercially viable model for AI-integrated primary care that bypasses traditional diagnostic silos.

2. Acorai: Pioneering Non-Invasive Cardiac Pressure Monitoring

Acorai is addressing one of the most significant unmet needs in cardiovascular medicine: the non-invasive measurement of intracardiac pressure. Traditionally, monitoring heart failure requires invasive right-heart catheterisation, a procedure that is costly and carries clinical risks. Acorai’s handheld heart monitor utilizes a combination of sensors and machine learning to provide accurate pressure readings without the need for surgery.

The company has successfully concentrated on high-tech solutions with direct clinical impact, a focus that has attracted international clinical partnerships. As hospital systems increasingly adopt value-based care models, technology that can reduce readmission rates for heart failure patients, by enabling better at-home management, will command premium valuations. Acorai is positioned as a primary target for cardiovascular leaders such as Boston Scientific or Abbott.

3. Sigrid Therapeutics: Strategic Disruptor in Metabolic Health

Sigrid Therapeutics is capitalizing on the global demand for metabolic health solutions, positioning its SiPore technology as a non-drug alternative to highly popular but expensive GLP-1 agonists like Ozempic. The SiPore platform consists of engineered silica particles that are ingested orally to physically prevent the absorption of certain digestive enzymes, thereby aiding in blood sugar and weight control.

The company raised SEK 45 million in January 2026, reaching a post-money valuation of SEK 600 million. More importantly, sales of its Glucose Stabiliser product in the U.S. tripled in 2025, and reports indicate that the company has engaged the investment bank Rothschild to evaluate M&A or IPO options. Sigrid represents a unique opportunity for consumer health giants (e.g., Kenvue) or specialised metabolic health firms looking to broaden their portfolios with scientifically-backed, non-pharmaceutical products.

4. Elypta: Metabolism-Based Liquid Biopsy Innovation

Elypta is a deep-tech scale-up that has pioneered a novel approach to early cancer detection through metabolism-based liquid biopsy. While most liquid biopsy firms focus on circulating tumour DNA (ctDNA), Elypta measures the "GAGome", a panel of glycosaminoglycan biomarkers that reflect the metabolic changes occurring very early in cancer development. By using algorithms trained to detect these specific signatures, Elypta can non-invasively identify cancer in blood or urine samples.

The company is currently conducting the largest study ever undertaken in kidney cancer recurrence monitoring and is a main partner in the €13.6 million EU-funded PREDI-LYNCH project for hereditary cancer screening. Elypta’s approach is fundamentally different from the rest of the market, offering a unique "secret sauce" for early detection that is highly attractive to pharmaceutical companies seeking companion diagnostics.

5. Flow Neuroscience: The World Leader in At-Home Neuromodulation

Flow Neuroscience has transformed the treatment landscape for Major Depressive Disorder (MDD) with its FDA-approved, at-home brain stimulation headset. The device uses Transcranial Direct Current Stimulation (tDCS) to deliver a low electrical current to the left dorsolateral prefrontal cortex, a region of the brain typically under active in patients with depression.

The company’s randomised controlled trial, published in Nature Medicine, demonstrated that 58% of patients achieved remission after ten weeks of use, results comparable to leading antidepressants but with minimal side effects.With over 55,000 users already in the EU and UK, and a planned U.S. commercial launch in Q2 2026, Flow Neuroscience is the premier target for strategic acquirers in the digital mental health and neuro-stimulation segments.

6. Hemab Therapeutics: Scaling the "Ultimate Clotting Company"

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing prophylactic treatments for serious, underserved bleeding disorders. The company closed an oversubscribed $157 million Series C round in October 2025, reflecting intense investor interest in its pipeline, which includes the first-ever prophylactic treatment for Glanzmann thrombasthenia (sutacimig).

Hemab’s strategy targets conditions that have historically been overlooked due to perceived market size, yet represent high unmet medical needs. By moving away from reactive "replacement" therapies toward monthly prophylactic antibody treatments, Hemab is redefining the treatment paradigm for rare coagulation disorders. Its high-quality investor syndicate, including Novo Holdings and Sofinnova Partners, signals a potential path toward a multi-billion dollar exit or IPO in 2026.

7. Anocca: Precision TCR-T Cell Therapy at Scale

Anocca is a biopharmaceutical firm that has developed a proprietary platform to decode T-cell biology with high precision. Its leading candidate, VIDAR-1, is Europe’s first non-viral gene-edited TCR-T cell therapy, currently in Phase I trials for mutant KRAS-positive pancreatic cancer. The company’s "systematization" approach allows for the high-throughput generation of TCR libraries, addressing the historic challenges of targeting solid tumours.

Anocca’s fully integrated model includes in-house cGMP manufacturing and a custom software ecosystem (AnoccaOS), reducing the reliance on external partners and accelerating development timelines. In August 2025, Anocca raised $46 million to fund its multi-centre clinical trials, positioning it as a top-tier candidate for acquisition by oncology-focused giants like AstraZeneca or Novartis.

8. Capitainer: Leading the Shift to Decentralised Clinical Sampling

Capitainer provides patient-centric solutions for the self-sampling of blood, plasma, and urine. Its patented technology ensures that patients can collect exact volumes of fluid from a fingertip prick, which can then be mailed to a laboratory without refrigeration or specialized packaging. This technology is critical for the growth of decentralised clinical trials and home-based health monitoring.

The company has successfully expanded its U.S. presence, inaugurating its own laboratory to support growing sales initiatives across Europe and North America. In October 2025, it launched the DIP70 device for dried urine microsampling, broadening its application to genomics, therapeutic drug monitoring and wellness screening. With over $18.7 Million raised and a generating revenue status, Capitainer is a prime target for diagnostic service providers like Labcorp or Quest Diagnostics.

9. Verigraft: Breakthroughs in Personalized Tissue Engineering

Gothenburg-based Verigraft has developed a regenerative medicine platform that transforms donated tissue into personalized vascular transplants. This unique technology removes the risk of graft rejection and eliminates the need for lifelong immunosuppression, a major milestone in tissue engineering.

In early 2026, Verigraft secured SEK 110 Million to advance its personalised tissue-engineered veins (P-TEV) through pivotal Phase II and III trials for Chronic Venous Insufficiency (CVI). CVI affects over four million people in the U.S. and Europe, representing a massive market with no currently effective long-term curative options. Verigraft’s Arvid Carlsson Award-winning technology makes it a high-potential target for medtech leaders in the vascular and regenerative space.

10. Suturion: Standardising Abdominal Wall Closure

Suturion is a Lund-based firm that has developed SutureTOOL, a specialized device designed to improve the consistency and safety of abdominal wall closure during surgery. The device facilitates the "small-bites" technique, which studies have shown can drastically reduce the occurrence of incisional hernias and wound dehiscence.

Following FDA clearance in the U.S., Suturion received the CE mark in 2025, opening the door for a broad European launch. The company is currently scaling production and planning its largest funding round to date to support international commercialisation. Suturion’s focus on reducing healthcare costs through standardised surgical outcomes aligns perfectly with the procurement goals of large hospital networks.

11. AMRA Medical: MRI-Based Body Composition Analysis

AMRA Medical is pioneering the use of MRI to profile body composition with extreme precision. Their technology measures fat and muscle volume and distribution, providing insights into metabolic health that far exceed the utility of Body Mass Index (BMI). AMRA’s data is increasingly used in pharmaceutical clinical trials to evaluate the efficacy of drugs for obesity, sarcopenia, and neuromuscular disorders.

As the global healthcare market pivots toward treating obesity with GLP-1 agonists, the need for precise body composition monitoring has surged. AMRA is a critical "picks and shovels" player in this segment, providing the analytical tools required to validate the next generation of weight loss therapies.

12. Saga Diagnostics: Leading Liquid Biopsy Monitoring

Saga Diagnostics is a Lund-based firm specializing in ultrasensitive cancer monitoring through liquid biopsy. Their technology is capable of detecting cancer-specific genetic variants at a frequency as low as 0.001 %, allowing for the detection of minimal residual disease and early recurrence.

The company has raised over $20.4 Million and maintains close partnerships with pharmaceutical firms for use in clinical trials. Saga's ability to offer higher sensitivity than many established competitors makes it an attractive acquisition target for global diagnostic giants seeking to enhance their oncology portfolios.

13. Doctrin: Operational Efficiency in Care Navigation

Doctrin provides a care navigation and digital triage platform that helps healthcare providers manage patient flow more effectively. The platform's ability to guide patients to the appropriate point of care, whether virtual or in-person, addresses the critical workforce shortages currently facing European health systems.

Part of the Ramsay Santé group in certain markets, Doctrin has demonstrated that digital transformation can enrich the patient experience while improving clinic productivity. Its focus on operational efficiency makes it highly relevant for large-scale health systems and private insurers looking to reduce administrative burdens.

14. Geras Solutions: Scalable Digital Dementia Assessments

Geras Solutions is at the forefront of digitalising dementia assessments, providing tools that drastically shorten the time required for cognitive investigations. Their platform is co-created with clinicians and validated through research at Karolinska University Hospital, showing improved precision compared to traditional "gold standard" tests like MoCA.

With the Swedish government investing SEK 100 Million in dementia care for 2025–2027, Geras Solutions is ideally positioned to benefit from increased national focus on early diagnosis. The company’s transition from Class I to Class IIa under the MDR is a key milestone for its international expansion strategy.

15. NuvoAir: Decentralising Chronic Respiratory Care

NuvoAir is a digital healthcare company that focuses on chronic respiratory disease management and decentralised clinical trials (DCTs). Their platform combines remote monitoring hardware with proprietary biomarkers to provide continuous care for patients with asthma and COPD.

Backed by Hikma Ventures and Industrifonden, NuvoAir has raised $25 Million and is actively expanding its footprint in the U.S. and Europe. Their dual-focus model—supporting both clinical care and pharmaceutical trials—makes them a versatile player in the rapidly growing DCT market.

16. Videm: Point-of-Care Molecular Diagnostics

Videm is developing a handheld, low-cost molecular diagnostic device for the rapid detection of viral and bacterial infections. Based in Gothenburg, the company uses innovative nucleic acid amplification to provide lab-quality results in decentralised settings.

Videm has been recognized as one of Sweden’s "rising stars" and has secured significant grant funding to advance its product development. Its focus on combating antimicrobial resistance through precise, rapid diagnosis aligns with global health priorities, making it a high-potential seed-to-scale candidate.

17. Hansa Biopharma: Global Leader in Immunomodulation

Hansa Biopharma is a commercial-stage biotechnology company that received the SwedenBIO Award 2025 for transforming Swedish scientific excellence into global medical impact. Its lead product, Idefirix, is a novel enzyme that enables kidney transplants in highly sensitised patients by cleaving IgG antibodies.

As the "bold guiding star" of the Swedish life science ecosystem, Hansa Biopharma is demonstrating how Swedish companies can build commercial capacity for global markets. Its continued success in transplantation and acute autoimmune diseases makes it a perennial target for large biopharma acquirers.

18. MedVasc: Innovating in Vascular Surgery

MedVasc is a development-stage medtech company nearing commercialisation for its proprietary vascular surgery tools.Having secured €2.2 Million in late 2025, the company is finalising regulatory documentation for market entry in 2026.

CEO Cathrin Johansson is leading the company’s transition from R&D to market expansion, with a primary focus on obtaining FDA clearance for the U.S. market. MedVasc represents the methodical, engineering-driven innovation that characterises the Lund medtech cluster.

19. AlixLabs: Nanotechnology for MedTech Manufacturing

AlixLabs, a Lund-based startup, raised $16.2 million in November 2025 to scale its proprietary nanotechnology for semiconductor and medical device manufacturing. Their technology enables more efficient production of complex nano-structures, which is increasingly relevant as medtech devices become smaller and more integrated with electronics.

AlixLabs is part of a broader trend of Swedish "deep tech" firms that provide essential manufacturing innovations for the next generation of smart implants and wearable sensors.

20. PeptiSystems: Advancing Peptide Drug Manufacturing

PeptiSystems, based in Uppsala, is a venture-backed firm developing advanced manufacturing solutions for peptide-based pharmaceuticals. As peptides become increasingly important in treating metabolic and autoimmune diseases, the need for sustainable and efficient production systems has grown.

PeptiSystems is positioned at the intersection of medtech and bioprocessing, providing the technological infrastructure required to scale the production of complex biologics.

M&A and Strategic Investment Outlook for 2026

The Swedish medtech M&A market is entering a phase of high-value consolidation. Global medtech deal value surged to $97.6 Billion in 2025, the highest level in over a decade, driven by "mega-deals" like Abbott's acquisition of Exact Sciences. However, the underlying trend is toward smaller, capability-focused acquisitions that strengthen core business units without the integration risks of large-scale mergers.

Predicted MedTech M&A Multiples and Targets for 2026

Sector	EV/Revenue Multiple	Strategic Buyer Rationale
Cardiovascular & Imaging	6x – 8x+	Driven by the need for AI-integrated diagnostic tools.
Remote Monitoring & SaaS	4x – 6x	Focused on expanding decentralised care and DCT capabilities.
Precision Diagnostics	5.5x – 7x	Targeting liquid biopsy and early cancer detection platforms.
Surgical Robotics	Premium above range	High barriers to entry and massive market expansion potential.

Analysis synthesized from J.P. Morgan and PwC industry outlooks.

For strategic acquirers, the "patent cliff" is a primary motivator. An estimated $104 Billion in pharmaceutical revenue is expected to be subject to patent expiry by 2028. To fill this revenue gap, Big Pharma is increasingly looking toward TechBio and medtech companies that offer validated assets in late-stage development. Swedish firms like Sigrid Therapeutics, Anocca and Hemab are ideally positioned to benefit from this strategic desperation.

Ecosystem Analysis: Hubs of Swedish Innovation

The concentration of Swedish medtech innovation is largely focused in three major clusters, each offering a unique set of institutional supports and scientific heritage.

The Stockholm-Uppsala Cluster

Home to major academic institutions like Karolinska Institutet and Uppsala University, this hub is the primary center for biopharma and digital health innovation. It hosts the headquarters of firms like Neko Health, Capitainer, and Geras Solutions. The Stockholm Science City Foundation and STUNS Life Science facilitate collaboration between researchers and private capital.

The Gothenburg Hub

Gothenburg is characterised by a strong culture of collaboration between science and engineering. It is home to the AstraZeneca BioVentureHub and the Sahlgrenska Science Park, which supports startups like Verigraft and Videm. The region has the highest concentration of natural scientists and engineers in Sweden's metropolitan regions.

The Lund-Malmö (Skåne) Cluster

Lund is a global leader in medtech and diagnostics, rooted in the success of firms like Gambro and Axis Communications. The Medicon Village and Lund University support a vibrant ecosystem of diagnostics and immunotherapy firms, including Saga Diagnostics and Cantargia. The proximity to Denmark’s Medicon Valley creates additional cross-border synergies for clinical trials and talent acquisition.

Future Outlook: Navigating the EHDS and AI Act

As the industry moves into 2026, two major European regulatory frameworks will reshape the operating environment. The EU AI Act, which takes full effect for medical devices by August 2026, will impose strict requirements on high-risk AI-driven diagnostic tools. Swedish firms that have already prioritised clinical validation and transparent AI governance, such as Neko Health and Elypta, will be best positioned to command premium valuations.

Simultaneously, the European Health Data Space (EHDS) will introduce dynamic data consent models and require deeper interoperability with EHR systems. While this creates a "strategic fault line" between existing opt-in models and mandated data sharing, it also empowers companies that can effectively monetize longitudinal health data. Swedish regions are investing heavily to ensure that their IT infrastructure is "AI-ready" and compliant with these new standards.

Conclusions and Professional Implications

The Swedish healthtech and medtech sectors are currently at their most dynamic point in a decade. The transition toward a "TechBio" model, where biology is increasingly defined by data, is being led by a cohort of companies that have moved beyond pilot stages into pivotal clinical trials and international commercialisation.

For venture capital and private equity investors, the focus has shifted from speculative bets toward "proof of impact," favouring firms with strong intellectual assets and clear regulatory pathways.

For strategic acquirers, Sweden offers a uniquely diverse and scientifically rigorous pipeline that is ideally suited to address the "patent cliff" and the shift toward value-based, decentralized care. The companies identified in this report, from the AI diagnostics of Neko Health to the regenerative tissue engineering of Verigraft, represent the forefront of this transformation. As 2026 approaches, the convergence of favorable regulatory conditions, increased regional infrastructure investment, and a maturing pool of international talent will continue to drive Sweden’s position as a global leader in healthcare innovation.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech